Heather A. Wakelee, MD
The scope of non–small cell lung cancer (NSCLC) has been progressively transforming every few months, with regulatory decisions and emerging regimens making their way through the pipeline, most recently with EGFR inhibitors and immunotherapy agents.
on Advanced Non–Small Cell Lung Cancer, Wakelee, associate professor of medicine (oncology) at the Stanford University Medical Center, discussed the latest developments with EGFR inhibitors and immunotherapy agents in NSCLC.
OncLive: You had a few presentations today. What did your lecture on on EGFR-mutant NSCLC encompass?
The field of EGFR
-mutant lung cancer keeps growing as far as the number of agents we have to help people. There has also been movement in the best testing techniques. Since EGFR
mutations were identified, the primary tests have been based on tissue. Now, there is a movement toward some of the liquid biopsies with plasma testing. There was the approval of the first one of those about 1 year ago to look for the primary activating mutations, and now for one of the resistance mutations, as well.
... to read the full story